JAN 03, 2018 06:54 PM PST

Most can skip fasting before new cholesterol test

A new way to calculate so-called “bad cholesterol” levels in the blood could eliminate inconvenient pre-test fasting for most people, a new study shows.

The method of estimating a patient’s LDL, or low-density lipoprotein, is significantly more accurate than the old one in people who eat before blood is drawn, researchers say.

“Although the new LDL calculation method is a bit more complex, the beauty is that it can be performed using information that is already collected in the blood sample for the standard lipid profile and automated in the lab’s computer system to give a more accurate result,” says Seth Martin, co-director of the Advanced Lipid Disorders Center and assistant professor of medicine at the Johns Hopkins University School of Medicine.

“Since non-fasting samples are now accurate, it’s more convenient for patients because they can come in anytime and don’t need to return for a second appointment if they have eaten.”

Martin and colleagues developed the new method in 2013. Other researchers in the United States and abroad have also found evidence for its greater accuracy.

Even with the new method, fasting yields even more accurate LDL results than eating before the test, researchers say. The differences with the newer method, however, are likely not clinically meaningful in the vast majority of cases.

For the study, that appears in Circulation, researchers compared the accuracy of the new LDL calculation method with the Friedewald method, developed in the late 1970s.

Martin’s team showed in 2013 that the Friedewald method underestimates LDL cholesterol levels, particularly in people with high triglycerides—fatty acids that tend to be higher in obese people and diabetes patients.

Triglyceride levels increase after eating. The Friedewald method was developed based on blood samples of people who had abstained from eating within hours before their blood was drawn. Fasting has remained a requirement for the calculation.

The Friedewald calculation is total cholesterol minus high-density lipoprotein—or “good” cholesterol—minus triglycerides divided by five. That equation applies a one-size-fits-all factor of five and does not take into account variations among individuals.

The new method uses a chart with 180 different factors to individualize a patient’s results, more accurately estimating LDL cholesterol. This calculation is total cholesterol minus HDL cholesterol minus triglycerides divided by a specific value from the chart.

The test doesn’t take any longer than the old and costs the same.

Researchers used data from a clinical repository at Johns Hopkins, drawing on information from more than 1.545 million patients. About two-thirds had fasted 10 to 12 hours before a blood draw, and a third had not. The laboratory directly measured total cholesterol, HDL, LDL, and other cholesterol components. The same laboratory measured triglycerides using a standardized assay.

Investigators compared fasting and non-fasting estimates using the Friedewald and new methods to the actual measured value of LDL cholesterol. In the real world, labs traditionally estimate cholesterol levels because direct measurement using ultracentrifugation is relatively expensive and time-consuming,

For the final analysis of 127,741 participants with LDL less than 70 milligrams per deciliter, non-fasting accuracy with the new method was 92 percent compared to 71 percent using the Friedewald method.

With the Friedewald method, readings for about 30 percent of non-fasting participants were off by more than 10 milligrams per deciliter. The comparable number with the new method was only 3 percent.

Researchers say that pre-test fasting may still be important for certain patients: those with high-risk of cardiovascular disease whose treatment might change based on a small inaccuracy in the LDL cholesterol calculation, those with a triglyceride disorder, or those who need to fast for other types of tests such as blood sugar.

The David and June Trone Family Foundation funded the study. Martin and coauthor Steven Jones are inventors of the new method, which Johns Hopkins has licensed to Quest Diagnostics. Martin is also a paid consultant to Quest. Johns Hopkins oversees the arrangement under its conflict of interest policies.

 

This article was originally posted on futurity.org

About the Author
  • The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists-including two Nobel laureates-work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
You May Also Like
APR 15, 2018
Genetics & Genomics
APR 15, 2018
Gene Mutation Associated with Intellectual Dysfunction ID'ed
Researchers has revealed a previously unknown genetic mutation that is correlated with a variety of serious intellectual disabilities....
MAY 14, 2018
Clinical & Molecular DX
MAY 14, 2018
Early Differences Between Benign and Malignant Tumors
Physicians are in need of a dependable diagnostic approach for distinguishing between benign and malignant tumors early-on. Once doctors can rule out that ...
MAY 28, 2018
Clinical & Molecular DX
MAY 28, 2018
Bacterial Toxin Linked to Inflammatory Bowel Disease
Scientists have found evidence that it's not a bacterium, but one of its toxins, that is connected to, and possibly causing intestinal dysfunction....
AUG 08, 2018
Microbiology
AUG 08, 2018
Use of Probiotics Linked to Severe Bloating, Brain Fog
Gut bacteria can have a powerful effect on brain function....
AUG 22, 2018
Clinical & Molecular DX
AUG 22, 2018
New Clinical Assay Useful For Urothelial Cancer
U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in u...
SEP 03, 2018
Clinical & Molecular DX
SEP 03, 2018
Patients fewer symptoms after these words from doctors
A few encouraging words about recovery time from a health care provider after an allergic reaction significantly reduces symptoms, according to a new study...
Loading Comments...